Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
复制标题
DOI：
10.1093/ofid/ofaa126
复制
发表时间：
2020-05-01
影响因子：
4.2
通讯作者：
Mio, Tadashi
中科院分区：
文献类型：
--
作者：
Fujita, Kohei;Yamamoto, Yuki;Mio, Tadashi
虽然它改善了肺癌，但免疫检查点抑制剂（ICI）的免疫疗法会引起包括结核病在内的感染性疾病的并发症。免疫治疗期间结核病的发病率尚不清楚。我们发现，1.7%的患者在我们机构的免疫治疗期间发展为活动性结核病。在ICI治疗前γ-干扰素释放试验阳性的患者中，医生应密切关注结核病的发展。
Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs) presents complications of infectious diseases, including tuberculosis. Incidence of tuberculosis during immunotherapy remains unclear. We found that 1.7% of patients developed active tuberculosis during immunotherapy at our institution. In patients with a positive interferon-gamma release assay status before ICI therapy, physicians should pay close attention to developing tuberculosis.